Alto Neuroscience/$ANRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alto Neuroscience
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Ticker
$ANRO
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
76
ISIN
US02157Q1094
Website
ANRO Metrics
BasicAdvanced
$63M
-
-$2.34
-
-
Price and volume
Market cap
$63M
52-week high
$17.55
52-week low
$1.60
Average daily volume
355K
Financial strength
Current ratio
22.533
Quick ratio
22.152
Long term debt to equity
18.377
Total debt to equity
19.007
Interest coverage (TTM)
-42.96%
Profitability
EBITDA (TTM)
-69.324
Management effectiveness
Return on assets (TTM)
-22.88%
Return on equity (TTM)
-38.04%
Valuation
Price to book
0.45
Price to tangible book (TTM)
0.45
Price to free cash flow (TTM)
-1.135
Free cash flow yield (TTM)
-88.09%
Free cash flow per share (TTM)
-203.50%
Growth
Earnings per share change (TTM)
-60.20%
What the Analysts think about ANRO
Analyst ratings (Buy, Hold, Sell) for Alto Neuroscience stock.
ANRO Financial Performance
Revenues and expenses
ANRO News
AllArticlesVideos
Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression
Business Wire·5 hours ago
Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203
Business Wire·4 days ago
Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alto Neuroscience stock?
Alto Neuroscience (ANRO) has a market cap of $63M as of June 30, 2025.
What is the P/E ratio for Alto Neuroscience stock?
The price to earnings (P/E) ratio for Alto Neuroscience (ANRO) stock is 0 as of June 30, 2025.
Does Alto Neuroscience stock pay dividends?
No, Alto Neuroscience (ANRO) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Alto Neuroscience dividend payment date?
Alto Neuroscience (ANRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Alto Neuroscience?
Alto Neuroscience (ANRO) does not currently have a Beta indicator.